Sunshine Nuohe Swings to Loss as Pipeline Advances
H1 2026 swing to net loss Sunshine Nuohe reported a first-half 2026 net loss of 24.4 million yuan, versus a 130 million yuan profit a year earlier, as revenue fell 27.81% to 426 million yuan. The absence of large out-licensing deals and pressure on pharma revenue drove the swing, weighing on the stock.
The loss is the core financial result that directly pressures the share price.
STC009 injection wins clinical trial approval A subsidiary received regulatory clearance to begin human testing of STC009, a Class 1 innovative drug for secondary hyperparathyroidism. This milestone advances the pipeline and signals progress in the company's peptide drug platform, supporting future value.
Clinical approval is a concrete pipeline win that can lift investor sentiment.
STC007 out-licensed and pipeline builds The interim report highlighted that self-developed STC007 for pruritus completed an out-licensing deal, STC008 for cancer cachexia is in trials, and multiple peptide, small nucleic acid, and CAR-T programs entered clinical stage. R&D spending rose to 20.54% of revenue, supporting long-term growth.
Pipeline progress and out-licensing show the innovation strategy is delivering, a positive counterweight to the loss.
Controlling shareholder sells 5% stake Controlling shareholder Li Qian transferred 5% of the company to a fund at 41.56 yuan per share for 233 million yuan. Control is unchanged and the buyer locked up for 12 months, but the sale adds supply and may raise governance or confidence questions.
The stake sale is a capital event that can affect supply and sentiment, though its impact is ambiguous.